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opportunities to grow. On the other side, the fierce competition among biosimilars 
with the same reference biologics and upcoming MNC’s next generation antibody 
therapies are also putting a threat to biosimilar market as a whole. ConClusions: 
If pathways cannot be tailor-made for biosimilars in the future, thus hinders the fast 
launch of biosimilar products in China, population may not be able to enjoy more 
cost effective treatments and government may also lose the chance to benefit from 
the saving of the total health care expenditure.
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objeCtives: There are challenges to assess the current situation of health care 
organizations’ waste management by the level and to formulate methods for fur-
ther improvement. Thus, purpose of this assessment study was to formulate ref-
erence about methods to improve current situation of health care organizations’ 
waste management. Methods: Study was done by the descriptive method among 
39 health care organizations using study forms, as questionnaires, checklist and 
tests. Results: In Ulaanbaatar waste disposal company is 100% responsible for 
hazardous waste of health care organizations, but 50% of domestic waste are taken 
care by hospitals themselves. However, in rural areas 48.7- 64% of hospitals and 
57.1% of health care centers are responsible for both their domestic and hazardous 
waste. 50% of hospitals drain the liquid waste into main sewage and liquid waste 
from laboratory are drained into central sewage after disinfection. Waste manage-
ment team works in 66.7% of hospitals, and nurses and dry-nurses are responsible 
in collecting of waste in 97.4% of hospitals. The team consists of 1-3 people in 
50% of hospitals, 4-6 people in 39.5% of hospitals but more people in tertiary level 
hospitals. ConClusions: Legal documents about waste management of health 
care organizations are approved; most secondary and tertiary level health care 
organizations have workers responsible for waste. They have developed plans to 
improve the “Waste management” and installed waste registration system. Despite 
setting up the temporary storages at hospitals and health care centers, they still 
need improvement. Although any equipment with mercury has been prohibited 
to use in health care organizations, 50% of hospitals are still using and it has been 
difficult to collect, transport and dispose mercury containing waste.
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objeCtives: This study is designed to review and to compare the concept and con-
tent of market access in both western and Chinese pharmaceutical environments, 
and further endeavor to clarify the responsibilities of each stakeholder in China to 
help providing better drug accessibility and affordability for the people. Methods: 
A literature review was undertaken to understand comprehensively the current 
market access protocols in mature markets as well as in China. Industry interviews, 
consulting surveys and data analysis were also conducted to collect first-hand data 
for comparison. Results: Unlike developed countries, where drug market access 
includes reimbursement and lots of patient access schemes, the market access of 
pharmaceuticals in China has a much broader scope, ranging from pricing, reim-
bursement, tendering, to hospital listing, etc, which indicates drug market access 
in China is a highly fragmented process and involves a lot of different govern-
ment departments. The centralized government management style, a historical 
consequence of the transformation from planned economy to market economy, 
is most attributable to this phenomenon. As a result, civil society, such as NGOs 
and academic institutions are relatively weaker compared to western countries, 
and they are not able to take intrinsically influential roles during market access 
decision-making process. This further leads to a high administration-oriented and 
low market-oriented drug market access present circumstance. Consequently, the 
timeline of drug market access in China is much longer than that of the mature 
market. ConClusions: The definition of market access in China needs to be re-
defined and global perspectives shall be incorporated. A re-structured concept will 
better serve China’s changing environment.
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objeCtives: Even the Ministry of Health is taking its attention to improve quality 
and safety of medical services, developing and implementing relevant policy and 
directions, quantity of complaints and occupational mistakes coming from citizens 
for medical services are still not going down. Therefore it is very necessary for every 
health organizations to analyze the situation. Methods: To study processes for evi-
dences and requirements of quality, information is collected by quantitave method 
and the cross sectional survey form was used. Results: On the service standard 
surveys taken from medical staffs, 56.6% in I level hospitals, 50.0% in II level hos-
pitals and 73.3% in III level hospitals are replied as they follow certain standards 
for their services. But respondents replied as 47.4% of the standards for medical 
services, which is the most percent, are not incompatible for wards. When summa-
rizing the results, we can say it is not clear what service standards the medical staffs 
cared for by the full-time intensivists had a shorter RCC and ventilator days, lower 
expenses and RCC transfer rates (p < 0.001), and higher weaning and complication 
rates (p < 0.05) than those cared for by the part-time and full-time responsible chest 
physicians. Risk factors for mortality variables including APACHE II, transfer to the 
ICU, RCC length of stays, and albumin level. APACHE II, types of physicians staffed, 
transfer to the ICU, RCC length of stays, and Creatinine were the risk factors affecting 
weaning rates in the RCC patients. ConClusions: There were differences in the 
overall use of health care resources and weaning rates among the patients cared 
for by full-time intensivitsts, part-time responsible chest physicians, and full-time 
responsible chest physicians but no difference in adjusting mortality.
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objeCtives: This study focuses on the regulations made by government of India for 
Nutraceuticals labeling requirements and the need of change in the monitoring system in 
the same our objectives for the study were: 1. to understand labeling regulations of 
Nutraceuticals in India. 2. To study labels of selected Nutraceutical products from 
health care market. Methods: For objective first we have studied the regulations 
made by FDA of India regarding Nutraceuticals labeling requirement, for which we 
have used secondary data collection method. For second objective we have collected 
30 samples randomly from Nutraceutical segments from local Pharmacies and stud-
ied the labels carefully. Results: The follow-up by Nutrceuticals manufacturer to 
labeling regulations found very moderate in our study. We found that regulations 
about list of ingredients, nutritional value, declaration regarding veg non-veg, dec-
laration regarding food additives and other crucial parts of label are poorly followed 
by Nutraceutical Manufacturer in India. ConClusions: As we have studied the 
regulations regarding labeling of Nutraceuticals, we found that this regulations are 
sufficient and appropriate. Again through this research work we come to make this 
conclusion that Nutraceutical manufacturer/importer in India are not that much 
serious regarding labeling which is threatening in some aspects so they used to 
make mistakes in labeling knowingly or unknowingly.
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objeCtives: To develop a method of setting a Drug Price Reference Index (DPRI) in 
the Philippines to ensure good value for money in the procurement and reimburse-
ment of essential medicines. Methods: A database of prevailing drug procurement 
prices was created from actual purchase orders submitted in 2012 by government 
procuring entities in the Philippines. The database includes information on the 
unit cost, volumes of procurement, source/supplier/manufacturer, brand, mode of 
procurement and location of the hospital for each formulation and strength of all 
drugs in the National Formulary. Univariate regression analyses were performed 
for commonly sourced essential drugs exploring possible determinants of drug 
costs, which include quantities procured and hospital bed capacity. Further cost-
comparisons were made for other potential determinants such as mode of procure-
ment, supplier/manufacturer and distance of distribution. Results: Price data was 
analyzed for 20 drug products with the highest share of procurement in terms of 
volume and value. Extreme wide variations in unit costs were consistently observed 
for all drugs analyzed. The price differentials, i. e. high/low ratio, was found to be up 
to 60 times when comparing the highest to the lowest priced drugs. The variations 
in prices were not associated by volumes procured, distance of distribution and 
hospital bed capacity. Suppliers were also observed to charge different prices for 
the same brands to different public hospitals, indicating information asymmetry 
on reasonable prices of drugs. ConClusions: Based on the observed wide varia-
tions in drug procurement prices in the Philippines, setting the DPRI at the median 
value for most drugs was found to be an appropriate method to set ceiling prices 
for public sector procurement. For monopolized pharmaceutical products, other 
methods may be more appropriate such as value-based pricing, price negotiations 
and external reference pricing to relevant countries.
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objeCtives: This study aims to review released policies with regards to biosimilar 
products in China, and further understand the external environment that shapes 
the biosimilar market. Methods: A literature review on laws, regulations and 
policies released by key government stakeholders and other additional docu-
ments was performed to fully capture the policy environment for biosimilars in 
China. Results: Multiple policies have been issued at central government level to 
encourage the development of biologics industry in China. Nevertheless, rather than 
in favor of accelerating market access for biologics, those policies are more R&D 
and manufacturing quality control focused. There is no clear regulatory pathway 
for biosimilars in China to date. Due to the lack of clear standard for biosimilars to 
prove their bioequivalence to the originators, biosimilars are treated as new drugs 
at each stage of market access, resulting in a delay of getting approval in China 
market. Currently, local biosimilar developers are actively building their capabilities 
in innovative biologics such as monoclonal antibodies, while MNC players are con-
tinuing to bring in new molecules. As original products’ patent expiry peak period 
is coming, biosimilars, whose prices are relatively affordable, have potential huge 
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drug manufacturers and the decision makers. This study reports the findings from 
a survey of pricing and reimbursement experts in Australia to gain insight into 
their attitude/opinions of RSAs from their own personal experience. Methods: 
Senior-level health economists and consultants were targeted. The survey included 
questions about responder’s demographics, the number and type of RSAs they have 
personally been involved with, and their experience and opinions about RSAs. A 
general overview of RSAs is also provided to better contextualise the survey find-
ings. Results: Ten experts participated on an anonymous basis. They in total have 
been involved in 403 submissions, and 56 RSAs of various types. Capped cost agree-
ments were most frequently employed (> 70% of all RSAs). ‘Hidden price’ is also 
frequently agreed. Respondents generally had positive attitude towards RSA (mean 
of 3 using a 1-5 scale) mainly because it can potentially benefit timeline and address 
global pricing issues. Concerns were however raised about the fact that the ‘risk’ is 
entirely borne by the industry in many cases and RSA has now become an integral 
element in the PBAC’s decision making process. ConClusions: RSA is generally 
well perceived among industry experts in Australia, whilst an increasing role of 
PBAC in defining clauses in the agreement is seen as a hurdle against productive 
involvement from the industry. The Australian model of RSA may offer a useful 
template for other jurisdictions.
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objeCtives: This study is designed to review current ‘risk-sharing’ schemes 
worldwide and in China, and further examine what kind of situations where 
‘risk-sharing’ schemes should be considered. Methods: A literature review 
was undertaken to identify existing schemes in developed countries. A review 
of released policies in China was also conducted to understand China’s current 
rules of practice. Cases studies were established for detailing agreement structure 
and potential impact on payers and industry. Results: Risk-sharing schemes are 
introduced to the market in the context of fast growing health care cost and uncer-
tain drug values. Nearly almost all of China’s scheme practices are financial-based 
agreements and don’t integrate drug’s real world performance. Unlike mature 
market, risk-sharing agreement in China is more often applied to established 
products rather than newly-entered innovative drugs. A typical successful agree-
ment in China has several must-have factors, including discounted drug price, 
purchase/free drug package and charity program. When considering a sustainable 
win-win risk-sharing scheme, a company must be very determined and assess its 
product carefully to decide whether the disease is in a high priority and there are 
currently few effective treatments; where policies can be leveraged and opportuni-
ties can be created for negotiation; whether strong lobbying message and product 
value proposition can be developed to meet the interests of the stakeholders; 
whether proposed scheme (price and additional service) can substantially lower 
health service cost as well as to enhance reimbursement; whether management 
team can ensure well-functioning operational capabilities for legal, administra-
tive and delivery support. ConClusions: With more innovative drugs being 
introduced to China market; ‘risk-sharing’ schemes will become more popular 
as national reimbursement drug list cannot immediately cover the increasing 
cost. Global experience also suggests there is a trend that ‘risk-sharing’ agree-
ment will be more often considered as a market access strategy for new products 
in the future.
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Dinh T.
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In the last three decades, evidence-based medicine (EBM) has been the driving 
force in shaping guidelines and clinical decision making in screening, prevention 
and treatment of diseases. Evidence review, evidence grading and meta-analysis 
of trials are standardized and routinely conducted. However, recent technological 
developments have significant impacts on future directions of EBM. With recent 
advances in health information technology, electronic medical records (EMRs), 
proteomics and genomics, clinical evidence has become increasingly abundant 
and diverse. At the same time, the inputs into medical decision making have also 
become increasingly complex. Model Based Medicine (MBM) has recently emerged 
as a framework to address the above challenges. MBM is the use of large-scale 
integrated physiology and pathology-driven mathematical models to translate and 
to synthesize existing evidence and medical knowledge into a unified framework, 
which will then be used to support clinical decision making at individual patient 
level. MBM not only incorporates all available evidence and most up-to-date 
understanding of diseases but also account for uncertainties in data and gaps in 
knowledge. MBM serves as an interface between evidence and physicians, allow-
ing rapid extraction of quantitative, robust and already synthesized information 
for customized clinical decision making. The decisions can be optimized not only 
based on the therapeutic efficacy of health interventions, current health status 
of patients but also patient’s health behavior (e. g. past likelihood to comply with 
treatment recommendations) and preferences. Based on our recent experience at 
Archimedes, I will present several case studies to illustrate the power of MBM in 
leveraging data from EHR and other data sources to support decision making at 
both population and individual level. I will also speak about the scientific and tech-
nical challenges faced by MBM and our strategy in addressing these challenges, 
including developments of standardized and automatic tools for data integration 
and synthesis, model calibration and validation, uncertainty quantification and 
optimal design for model-physician interface.
follow or they do not have customized service standards. Moreover, basing on the 
result, medical staffs have no common awareness what standards they must follow 
for their services, except awareness of treatment and diagnosis; there is insufficient 
information about service standards. ConClusions: One third of organizations 
attended in surveys operates their operations without the organization’s service 
standards. Service standards of an organization are developed by Medical directors, 
Quality department and Professional council. Service standards of organizations are 
not approved, there is no any control to implement service standards, or the service 
standards are inappropriate and no unfavorable environment to implement service 
standards. Even the control on “Common operation standards”’s implementation is 
good, no unfavorable environment to implement the standard. Moreover registration 
of mistakes related to “Common operation standards” is insufficient, measures and 
warnings to improve the low indication of mistakes are not taken well.
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objeCtives: Priority setting in the allocation of new medical interventions is 
increasingly based on formulated values. Before drafting the new medical service 
items and fee schedule, the National Health Insurance Act of Taiwan identifies 
four prioritizing rules -human health, medical ethics, cost-effectiveness, and the 
finances of the Insurance respectively to compliance with. Our study objectives 
are to compare the policy makers’ actual value preferences with these four official 
formulated principles and to guide the Ministry of Health and Welfare in Taiwan 
in the priority setting of new medical interventions. Methods: We used a mul-
ticriteria decision analytical framework. In total 65 respondents participated in 
a discrete choice experiment to weigh their relative importance of six selected 
policy criteria for priority setting. Regression analysis was used to rank order a set 
of new recently adopted medical interventions on the basis of these criteria and 
related to weights. Results: Policymakers considered severity of disease, people 
of middle-age, cost effectiveness as the most important criteria for priority setting 
of interventions, followed by low budget impact. Signs of coefficients of many ben-
eficiaries and large individual benefits did not have the expected direction. Certain 
interventions in HIV Ag/Ab test, HLA-B 1502 gene typing, HCV Genotyping Test and 
orthopedic surgery rank highest. Cochlear implant ranks 12th out of 22 medical 
interventions. ConClusions: Policy makers’ values are partially in agreement with 
principles formulated in National Health Insurance laws. Multi-criteria decision 
approaches may provide a tool to guide explicit allocation decisions.
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objeCtives: Having maintained close association with China through the ages, a 
number of traditional Chinese medicine hospitals have prevailed in South Korea 
despite abundance of western medicines. Given this prevalence of herbal medicinal 
therapy and the increasing health care expenditure, the purpose of this research is to 
explore the feasibility of formally establishing guidelines and conducting pharmaco-
economic evaluations for coverage selection of traditional Chinese medicine from the 
perspective of decision makers in the Republic of Korea. Methods: Research was 
conducted, using qualitative telephone and email-based interviews with individuals 
involved in Health Insurance Review & Assessment Service (HIRA) and KOLs in South 
Korea in order to gain a broad range of perspectives on the topic. The interviewees 
were asked to share their opinions on the significance and viability of developing for-
mal guidelines and performing economic evaluations for traditional herbal medicines. 
Moreover, they were asked to identify critical issues around applying established 
pharmacoeconomic guidelines to traditional medicinal therapy. Results: In the 
primary research, the majority of interviewees agreed on the importance of conduct-
ing pharmacoeconomic evaluations for traditional medicine. They recognised that 
a great amount of herbal medicine is produced and consumed. Patients pay for this 
medicine as out-of-pocket expense, although the outcomes are not well measured 
and understood by either the government or the public. Furthermore, they acknowl-
edged that existing pharmacoeconomic guidelines may not always be appropriate 
for making coverage decisions for these herbal treatments. Finally, they expected that 
separate guidelines specifically targeted at traditional medicine may develop, but not 
in a very near future. ConClusions: Given the extensive use of herbal medicine by 
the public, using pharmacoeconomic evaluation for reimbursement decision may 
encourage patients and physicians to choose more cost effective treatments and thus 
prevent the dramatic increase in total health care expenditure without demonstrated 
improvement in health outcomes.
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objeCtives: Conditional reimbursement approval for pharmaceuticals, for exam-
ple, risk-sharing arrangement (RSA) involving price-volume agreement or various 
post-launch monitoring requirements, is becoming a standard practice in Australia, 
especially for novel treatments with high ICER and/or potentially significant budget 
impact. Uptake of RSAs are relatively slow in other jurisdictions. Efficient implemen-
tation of an RSA requires active involvement from all stakeholders, in particular, 
